Serveur d'exploration H2N2

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Influenza (“Bird Flu”), inflammation and anti-inflammatory/analgesic drugs

Identifieur interne : 001545 ( Main/Exploration ); précédent : 001544; suivant : 001546

Influenza (“Bird Flu”), inflammation and anti-inflammatory/analgesic drugs

Auteurs : K. D. Rainsford [Royaume-Uni]

Source :

RBID : ISTEX:FDE28A8F221A75575CA444AFA4E9B7F5EEF76921

English descriptors

Abstract

Abstract.: The spectre of an influenza pandemic is being widely mooted. Most of the strategies explored to date for controlling or treating the condition have centred on controlling the spread of the infection, the use of vaccines or anti-viral agents. There has been relatively little discussion about treating the lung and systemic inflammatory reactions that occur during influenza infection. In this review a range of therapeutic agents are proposed to treat the inflammatory reactions, principally in the lung as well as the systemic cytokine-mediated immuno-inflammatory reactions that may be a major cause of the morbidity and mortality associated with influenza infections. Among these are pentoxifylline, the statins, the macrolide antibiotics (e.g. azithromycin, clarithromycin, erythromycin), resveratrol (a component of wine and fruits with inhibitory effects on influenza virus replication) and nutraceuticals (including those that contain flavonoids, the marine oils eicosapentanoic and docosanoic acids or the green-lipped mussel extract, Liprinol®) which may by virtue of the inhibitory effects on the production or actions of pro-inflammatory cytokines, be useful for their anti-inflammatory actions. The efficacy, mode of actions and side effects of non-steroidal anti-inflammatory drugs (NSAIDs) are considered. There are a number of issues relating to their use in treating the inflammatory reactions in the respiratory tract. Among these are the development of gastro-intestinal ulcers and bleeding and hepato-renal reactions in patients that may because of severe systemic inflammation be prone to the development of these adverse reactions. There are also theoretical issues concerning the impact of COX-1 mediating reduction in prostaglandin and increased cytokine production that might have some negative consequences for respiratory inflammation. In conclusion, further consideration should be given to exploring the actions of these anti-inflammatory agents to control the respiratory inflammatory in influenza infections which can have serious consequences for the outcome of the infection.

Url:
DOI: 10.1007/s10787-006-0002-5


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Influenza (“Bird Flu”), inflammation and anti-inflammatory/analgesic drugs</title>
<author>
<name sortKey="Rainsford, K D" sort="Rainsford, K D" uniqKey="Rainsford K" first="K. D." last="Rainsford">K. D. Rainsford</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:FDE28A8F221A75575CA444AFA4E9B7F5EEF76921</idno>
<date when="2006" year="2006">2006</date>
<idno type="doi">10.1007/s10787-006-0002-5</idno>
<idno type="url">https://api.istex.fr/ark:/67375/VQC-R6JH4XSQ-9/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001483</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001483</idno>
<idno type="wicri:Area/Istex/Curation">001483</idno>
<idno type="wicri:Area/Istex/Checkpoint">000475</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000475</idno>
<idno type="wicri:doubleKey">0925-4692:2006:Rainsford K:influenza:bird:flu</idno>
<idno type="wicri:Area/Main/Merge">001570</idno>
<idno type="wicri:Area/Main/Curation">001545</idno>
<idno type="wicri:Area/Main/Exploration">001545</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main" xml:lang="en">Influenza (“Bird Flu”), inflammation and anti-inflammatory/analgesic drugs</title>
<author>
<name sortKey="Rainsford, K D" sort="Rainsford, K D" uniqKey="Rainsford K" first="K. D." last="Rainsford">K. D. Rainsford</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Biomedical Research Centre, Sheffield Hallam University, Howard Street, S1 1WB, Sheffield</wicri:regionArea>
<wicri:noRegion>Sheffield</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1">
<country wicri:rule="url">Royaume-Uni</country>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">InflammoPharmacology</title>
<title level="j" type="sub">Experimental and Clinical Studies</title>
<title level="j" type="abbrev">Inflammopharmacol</title>
<idno type="ISSN">0925-4692</idno>
<idno type="eISSN">1568-5608</idno>
<imprint>
<publisher>Birkhäuser-Verlag; www.birkhauser.ch</publisher>
<pubPlace>Basel</pubPlace>
<date type="published" when="2006-03-01">2006-03-01</date>
<biblScope unit="volume">14</biblScope>
<biblScope unit="issue">1-2</biblScope>
<biblScope unit="page" from="2">2</biblScope>
<biblScope unit="page" to="9">9</biblScope>
</imprint>
<idno type="ISSN">0925-4692</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0925-4692</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Anti-inflammatory</term>
<term>Anti-oxidants</term>
<term>Bird-flu</term>
<term>Influenza</term>
<term>NSAIDs</term>
<term>Nutraceuticals</term>
<term>Respiratory</term>
<term>Resveratrol</term>
</keywords>
</textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Abstract.: The spectre of an influenza pandemic is being widely mooted. Most of the strategies explored to date for controlling or treating the condition have centred on controlling the spread of the infection, the use of vaccines or anti-viral agents. There has been relatively little discussion about treating the lung and systemic inflammatory reactions that occur during influenza infection. In this review a range of therapeutic agents are proposed to treat the inflammatory reactions, principally in the lung as well as the systemic cytokine-mediated immuno-inflammatory reactions that may be a major cause of the morbidity and mortality associated with influenza infections. Among these are pentoxifylline, the statins, the macrolide antibiotics (e.g. azithromycin, clarithromycin, erythromycin), resveratrol (a component of wine and fruits with inhibitory effects on influenza virus replication) and nutraceuticals (including those that contain flavonoids, the marine oils eicosapentanoic and docosanoic acids or the green-lipped mussel extract, Liprinol®) which may by virtue of the inhibitory effects on the production or actions of pro-inflammatory cytokines, be useful for their anti-inflammatory actions. The efficacy, mode of actions and side effects of non-steroidal anti-inflammatory drugs (NSAIDs) are considered. There are a number of issues relating to their use in treating the inflammatory reactions in the respiratory tract. Among these are the development of gastro-intestinal ulcers and bleeding and hepato-renal reactions in patients that may because of severe systemic inflammation be prone to the development of these adverse reactions. There are also theoretical issues concerning the impact of COX-1 mediating reduction in prostaglandin and increased cytokine production that might have some negative consequences for respiratory inflammation. In conclusion, further consideration should be given to exploring the actions of these anti-inflammatory agents to control the respiratory inflammatory in influenza infections which can have serious consequences for the outcome of the infection.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Royaume-Uni</li>
</country>
</list>
<tree>
<country name="Royaume-Uni">
<noRegion>
<name sortKey="Rainsford, K D" sort="Rainsford, K D" uniqKey="Rainsford K" first="K. D." last="Rainsford">K. D. Rainsford</name>
</noRegion>
<name sortKey="Rainsford, K D" sort="Rainsford, K D" uniqKey="Rainsford K" first="K. D." last="Rainsford">K. D. Rainsford</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001545 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001545 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    H2N2V1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:FDE28A8F221A75575CA444AFA4E9B7F5EEF76921
   |texte=   Influenza (“Bird Flu”), inflammation and anti-inflammatory/analgesic drugs
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 14 19:59:40 2020. Site generation: Thu Mar 25 15:38:26 2021